{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T01:49:57Z","timestamp":1792028997937,"version":"4.4.0"},"reference-count":91,"publisher":"BMJ","issue":"4","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Thorax"],"accepted":{"date-parts":[[2025,6,13]]},"published-print":{"date-parts":[[2026,4]]},"abstract":"<jats:p>Sepsis is a life-threatening syndrome driven by a dysregulated host response to infection. Immune dysregulation arises from responses that initially were activated to protect against pathogens and preserve tissue integrity. Disturbed resistance mechanisms can result in excessive inflammation alongside immunosuppression, each of which is considered important biological drivers of the immunopathology of sepsis. Key inflammatory drivers are excessive proinflammatory cytokine activity, complement and coagulation system activation and endothelial dysfunction. Conversely, sepsis-induced immunosuppression is marked by lymphocyte exhaustion, reduced monocyte human leucocyte antigen-DR expression, and the emergence of myeloid-derived suppressor cells. Within this complex immunological environment, the gut microbiome influences host immunity through the release of short-chain fatty acids and bacterial metabolites. Thus far, immunomodulatory trials in patients with sepsis paid little attention to the identification of dominant biological drivers, which might enrich the population for those who are more likely to respond to a certain intervention. Recently, retrospective analyses of such trials, as well as small prospective trials, have provided proof of concept that subgroups of sepsis patients can be identified with specific immunological profiles, either based on a single biomarker or on high-dimensional data, that respond differently to immunomodulation. This review explores the biological drivers of sepsis immunopathology, highlighting the challenges in translating preclinical insights into effective therapies and the potential of personalised medicine approaches to improve sepsis outcomes.<\/jats:p>","DOI":"10.1136\/thorax-2024-222012","type":"journal-article","created":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T13:25:14Z","timestamp":1751462714000},"page":"396-403","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":14,"title":["Biological drivers of the host response in sepsis"],"prefix":"10.1136","volume":"81","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2277-1343","authenticated-orcid":false,"given":"W Joost","family":"Wiersinga","sequence":"first","affiliation":[{"name":"Centre of Infection and Molecular Medicine & Division of Infectious Diseases, Amsterdam University Medical Centre, University of Amsterdam, Amsterdam, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9199-5079","authenticated-orcid":false,"given":"Tom","family":"van der Poll","sequence":"additional","affiliation":[{"name":"Centre of Infection and Molecular Medicine & Division of Infectious Diseases, Amsterdam University Medical Centre, University of Amsterdam, Amsterdam, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2025,7,2]]},"reference":[{"key":"2026042806000671000_81.4.396.1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2016.0287"},{"key":"2026042806000671000_81.4.396.2","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/S0140-6736(19)32989-7","article-title":"Global, regional, and national sepsis incidence and mortality, 1990\u20132017: analysis for the Global Burden of Disease Study","volume":"395","author":"Rudd","year":"2020","journal-title":"The Lancet"},{"key":"2026042806000671000_81.4.396.3","doi-asserted-by":"crossref","DOI":"10.1186\/s13054-024-04964-6","article-title":"Towards personalized medicine: a scoping review of immunotherapy in sepsis","volume":"28","author":"Slim","year":"2024","journal-title":"Crit Care"},{"key":"2026042806000671000_81.4.396.4","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/S2213-2600(23)00330-2","article-title":"Profiling the dysregulated immune response in sepsis: overcoming challenges to achieve the goal of precision medicine","volume":"12","author":"Cajander","year":"2024","journal-title":"Lancet Respir Med"},{"key":"2026042806000671000_81.4.396.5","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2021.10.012"},{"key":"2026042806000671000_81.4.396.6","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/S2213-2600(23)00468-X","article-title":"Reframing sepsis immunobiology for translation: towards informative subtyping and targeted immunomodulatory therapies","volume":"12","author":"Shankar-Hari","year":"2024","journal-title":"Lancet Respir Med"},{"key":"2026042806000671000_81.4.396.7","doi-asserted-by":"publisher","DOI":"10.1378\/chest.101.6.1481"},{"key":"2026042806000671000_81.4.396.8","doi-asserted-by":"publisher","DOI":"10.1126\/science.1214935"},{"key":"2026042806000671000_81.4.396.9","doi-asserted-by":"crossref","first-page":"293","DOI":"10.37349\/ei.2022.00051","article-title":"Janus face of sepsis: a viewpoint","volume":"2","author":"Bauer","year":"2022","journal-title":"Explor Immunol"},{"key":"2026042806000671000_81.4.396.10","doi-asserted-by":"publisher","DOI":"10.1111\/imr.12499"},{"key":"2026042806000671000_81.4.396.11","doi-asserted-by":"publisher","DOI":"10.1007\/s00134-021-06574-0"},{"key":"2026042806000671000_81.4.396.12","doi-asserted-by":"crossref","DOI":"10.1177\/1178636118825081","article-title":"Characterization of Pathogenic Sepsis Etiologies and Patient Profiles: A Novel Approach to Triage and Treatment","volume":"12","author":"Dolin","year":"2019","journal-title":"Microbiol Insights"},{"key":"2026042806000671000_81.4.396.13","doi-asserted-by":"crossref","first-page":"105799","DOI":"10.1016\/j.ebiom.2025.105799","article-title":"Pathogen-specific host response in critically ill patients with blood stream infections: a nested case-control study","volume":"117","author":"Butler","year":"2025","journal-title":"EBioMedicine"},{"key":"2026042806000671000_81.4.396.14","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01856-2021","article-title":"Blood leukocyte transcriptomes in Gram-positive and Gram-negative community-acquired pneumonia","volume":"59","author":"Pereverzeva","year":"2022","journal-title":"Eur Respir J"},{"key":"2026042806000671000_81.4.396.15","doi-asserted-by":"publisher","DOI":"10.1007\/S00134-021-06506-Y"},{"key":"2026042806000671000_81.4.396.16","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200205-446OC"},{"key":"2026042806000671000_81.4.396.17","doi-asserted-by":"publisher","DOI":"10.1097\/CCM.0000000000006119"},{"key":"2026042806000671000_81.4.396.18","doi-asserted-by":"crossref","DOI":"10.1155\/2013\/165974","article-title":"Cytokines in sepsis: potent immunoregulators and potential therapeutic targets--an updated view","volume":"2013","author":"Schulte","year":"2013","journal-title":"Mediators Inflamm"},{"key":"2026042806000671000_81.4.396.19","doi-asserted-by":"publisher","DOI":"10.1097\/01.CCM.0000145229.59014.6C"},{"key":"2026042806000671000_81.4.396.20","doi-asserted-by":"publisher","DOI":"10.1097\/00003246-199707000-00010"},{"key":"2026042806000671000_81.4.396.21","doi-asserted-by":"publisher","DOI":"10.1097\/CCM.0000000000001402"},{"key":"2026042806000671000_81.4.396.22","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1097\/CCM.0000000000002749","article-title":"Mortality Benefit of Recombinant Human Interleukin-1 Receptor Antagonist for Sepsis Varies by Initial Interleukin-1 Receptor Antagonist Plasma Concentration*","volume":"46","author":"Meyer","year":"2018","journal-title":"Crit Care Med"},{"key":"2026042806000671000_81.4.396.23","doi-asserted-by":"crossref","first-page":"100817","DOI":"10.1016\/j.xcrm.2022.100817","article-title":"Toward personalized immunotherapy in sepsis: The PROVIDE randomized clinical trial","volume":"3","author":"Leventogiannis","year":"2022","journal-title":"Cell Reports Medicine"},{"key":"2026042806000671000_81.4.396.24","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2022-067251","article-title":"ImmunoSep (Personalised Immunotherapy in Sepsis) international double-blind, double-dummy, placebo-controlled randomised clinical trial: study protocol","volume":"12","author":"Kotsaki","year":"2022","journal-title":"BMJ Open"},{"key":"2026042806000671000_81.4.396.25","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1016\/S2213-2600(23)00158-3","article-title":"Prospective evaluation of the efficacy, safety, and optimal biomarker enrichment strategy for nangibotide, a TREM-1 inhibitor, in patients with septic shock (ASTONISH): a double-blind, randomised, controlled, phase 2b trial","volume":"11","author":"Fran\u00e7ois","year":"2023","journal-title":"Lancet Respir Med"},{"key":"2026042806000671000_81.4.396.26","doi-asserted-by":"publisher","DOI":"10.1002\/1873-3468.13881"},{"key":"2026042806000671000_81.4.396.27","doi-asserted-by":"publisher","DOI":"10.1038\/nri3345"},{"key":"2026042806000671000_81.4.396.28","doi-asserted-by":"publisher","DOI":"10.1213\/ANE.0000000000006888"},{"key":"2026042806000671000_81.4.396.29","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2019.5358"},{"key":"2026042806000671000_81.4.396.30","doi-asserted-by":"publisher","DOI":"10.1097\/CCM.0000000000004426"},{"key":"2026042806000671000_81.4.396.31","doi-asserted-by":"crossref","DOI":"10.1186\/s13054-022-04020-1","article-title":"Web-based application for predicting the potential target phenotype for recombinant human thrombomodulin therapy in patients with sepsis: analysis of three multicentre registries","volume":"26","author":"Goto","year":"2022","journal-title":"Crit Care"},{"key":"2026042806000671000_81.4.396.32","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201910-1911TR"},{"key":"2026042806000671000_81.4.396.33","doi-asserted-by":"publisher","DOI":"10.1093\/cvr\/cvaa070"},{"key":"2026042806000671000_81.4.396.34","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2018.00292","article-title":"Adrenomedullin and Adrenomedullin-Targeted Therapy As Treatment Strategies Relevant for Sepsis","volume":"9","author":"Geven","year":"2018","journal-title":"Front Immunol"},{"key":"2026042806000671000_81.4.396.35","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-physiol-061121-040214"},{"key":"2026042806000671000_81.4.396.36","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2019.01.019"},{"key":"2026042806000671000_81.4.396.37","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-020-0752-4"},{"key":"2026042806000671000_81.4.396.38","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-023-01490-5"},{"key":"2026042806000671000_81.4.396.39","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccc.2019.08.006"},{"key":"2026042806000671000_81.4.396.40","doi-asserted-by":"publisher","DOI":"10.1097\/SLA.0000000000001783"},{"key":"2026042806000671000_81.4.396.41","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201606-1143OC"},{"key":"2026042806000671000_81.4.396.42","doi-asserted-by":"publisher","DOI":"10.1002\/cyto.b.21270"},{"key":"2026042806000671000_81.4.396.43","doi-asserted-by":"publisher","DOI":"10.1016\/j.coi.2013.05.006"},{"key":"2026042806000671000_81.4.396.44","doi-asserted-by":"publisher","DOI":"10.1038\/nm0697-678"},{"key":"2026042806000671000_81.4.396.45","doi-asserted-by":"crossref","DOI":"10.1186\/s12879-019-4526-x","article-title":"Multicentric experience with interferon gamma therapy in sepsis induced immunosuppression. A case series","volume":"19","author":"Payen","year":"2019","journal-title":"BMC Infect Dis"},{"key":"2026042806000671000_81.4.396.46","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.98960","article-title":"Interleukin-7 restores lymphocytes in septic shock: the IRIS-7 randomized clinical trial","volume":"3","author":"Francois","year":"2018","journal-title":"JCI Insight"},{"key":"2026042806000671000_81.4.396.47","doi-asserted-by":"publisher","DOI":"10.1097\/SHK.0000000000001443"},{"key":"2026042806000671000_81.4.396.48","doi-asserted-by":"publisher","DOI":"10.1097\/CCM.0000000000003685"},{"key":"2026042806000671000_81.4.396.49","doi-asserted-by":"publisher","DOI":"10.1007\/s00134-019-05704-z"},{"key":"2026042806000671000_81.4.396.50","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/S2468-1253(16)30119-4","article-title":"The role of the gut microbiota in sepsis","volume":"2","author":"Haak","year":"2017","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2026042806000671000_81.4.396.51","doi-asserted-by":"crossref","DOI":"10.1186\/s13054-020-02989-1","article-title":"The gut microbiome\u2019s role in the development, maintenance, and outcomes of sepsis","volume":"24","author":"Adelman","year":"2020","journal-title":"Crit Care"},{"key":"2026042806000671000_81.4.396.52","doi-asserted-by":"crossref","first-page":"100864","DOI":"10.1016\/S2666-5247(24)00079-X","article-title":"Association between butyrate-producing gut bacteria and the risk of infectious disease hospitalisation: results from two observational, population-based microbiome studies","volume":"5","author":"Kullberg","year":"2024","journal-title":"Lancet Microbe"},{"key":"2026042806000671000_81.4.396.53","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20180399"},{"key":"2026042806000671000_81.4.396.54","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofae654","article-title":"Gut Microbiome in Human Melioidosis: Composition and Resistome Dynamics from Diagnosis to Discovery","volume":"11","author":"Chowdhury","year":"2024","journal-title":"Open Forum Infect Dis"},{"key":"2026042806000671000_81.4.396.55","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201503-0483OC"},{"key":"2026042806000671000_81.4.396.56","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2015-309728"},{"key":"2026042806000671000_81.4.396.57","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3542"},{"key":"2026042806000671000_81.4.396.58","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-024-01014-8"},{"key":"2026042806000671000_81.4.396.59","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2018.12.018"},{"key":"2026042806000671000_81.4.396.60","doi-asserted-by":"publisher","DOI":"10.1016\/j.chom.2024.01.002"},{"key":"2026042806000671000_81.4.396.61","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2021.10.013"},{"key":"2026042806000671000_81.4.396.62","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/S2213-2600(24)00257-1","article-title":"Empirical antibiotic therapy for sepsis: save the anaerobic microbiota","volume":"13","author":"Kullberg","year":"2025","journal-title":"Lancet Respir Med"},{"key":"2026042806000671000_81.4.396.63","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1322269111"},{"key":"2026042806000671000_81.4.396.64","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.550769","article-title":"HDAC3 Mediates the Inflammatory Response and LPS Tolerance in Human Monocytes and Macrophages","volume":"11","author":"Ghiboub","year":"2020","journal-title":"Front Immunol"},{"key":"2026042806000671000_81.4.396.65","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2018.04.022"},{"key":"2026042806000671000_81.4.396.66","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2018.00142","article-title":"The Metabolic Sensor GPR43 Receptor Plays a Role in the Control of Klebsiella pneumoniae Infection in the Lung","volume":"9","author":"Galv\u00e3o","year":"2018","journal-title":"Front Immunol"},{"key":"2026042806000671000_81.4.396.67","doi-asserted-by":"crossref","DOI":"10.1128\/mbio.01987-23","article-title":"Butyrate protects against MRSA pneumonia via regulating gut-lung microbiota and alveolar macrophage M2 polarization","volume":"14","author":"Zhao","year":"2023","journal-title":"MBio"},{"key":"2026042806000671000_81.4.396.68","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1038\/s41564-024-01882-9","article-title":"Enterobactin inhibits microbiota-dependent activation of AhR to promote bacterial sepsis in mice","volume":"10","author":"Keskey","year":"2025","journal-title":"Nat Microbiol"},{"key":"2026042806000671000_81.4.396.69","doi-asserted-by":"crossref","DOI":"10.1186\/s13054-024-05232-3","article-title":"A phase 2 randomized, placebo-controlled trial of inulin for the prevention of gut pathogen colonization and infection among patients admitted to the intensive care unit for sepsis","volume":"29","author":"Park","year":"2025","journal-title":"Crit Care"},{"key":"2026042806000671000_81.4.396.70","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-024-07502-0"},{"key":"2026042806000671000_81.4.396.71","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccc.2017.08.010"},{"key":"2026042806000671000_81.4.396.72","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201606-1225OC"},{"key":"2026042806000671000_81.4.396.73","doi-asserted-by":"crossref","DOI":"10.1186\/s13054-023-04536-0","article-title":"Plasma protein biomarkers reflective of the host response in patients developing Intensive Care Unit-acquired pneumonia","volume":"27","author":"van Engelen","year":"2023","journal-title":"Crit Care"},{"key":"2026042806000671000_81.4.396.74","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00592-2024","article-title":"The blood transcriptional response in patients developing intensive care unit-acquired pneumonia","volume":"65","author":"de Brabander","year":"2025","journal-title":"Eur Respir J"},{"key":"2026042806000671000_81.4.396.75","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-med-043021-014005"},{"key":"2026042806000671000_81.4.396.76","doi-asserted-by":"publisher","DOI":"10.1038\/s41581-019-0199-3"},{"key":"2026042806000671000_81.4.396.77","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.202311-2086SO"},{"key":"2026042806000671000_81.4.396.78","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDra2200118","article-title":"Immune Modulation in Sepsis, ARDS, and Covid-19 - The Road Traveled and the Road Ahead","volume":"1","author":"Leligdowicz","year":"2022","journal-title":"NEJM Evid"},{"key":"2026042806000671000_81.4.396.79","doi-asserted-by":"crossref","DOI":"10.1093\/burnst\/tkae073","article-title":"Aiming for precision: personalized medicine through sepsis subtyping","volume":"13","author":"Kolodyazhna","year":"2025","journal-title":"Burns Trauma"},{"key":"2026042806000671000_81.4.396.80","doi-asserted-by":"publisher","DOI":"10.1055\/s-0044-1787992"},{"key":"2026042806000671000_81.4.396.81","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/S2213-2600(16)00046-1","article-title":"Genomic landscape of the individual host response and outcomes in sepsis: a prospective cohort study","volume":"4","author":"Davenport","year":"2016","journal-title":"Lancet Respir Med"},{"key":"2026042806000671000_81.4.396.82","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201608-1685OC"},{"key":"2026042806000671000_81.4.396.83","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1016\/S2213-2600(17)30294-1","article-title":"Classification of patients with sepsis according to blood genomic endotype: a prospective cohort study","volume":"5","author":"Scicluna","year":"2017","journal-title":"Lancet Respir Med"},{"key":"2026042806000671000_81.4.396.84","doi-asserted-by":"publisher","DOI":"10.1097\/CCM.0000000000003084"},{"key":"2026042806000671000_81.4.396.85","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1016\/S2213-2600(23)00237-0","article-title":"Identifying molecular phenotypes in sepsis: an analysis of two prospective observational cohorts and secondary analysis of two randomised controlled trials","volume":"11","author":"Sinha","year":"2023","journal-title":"Lancet Respir Med"},{"key":"2026042806000671000_81.4.396.86","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.202308-1328OC"},{"key":"2026042806000671000_81.4.396.87","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201807-1419OC"},{"key":"2026042806000671000_81.4.396.88","doi-asserted-by":"crossref","unstructured":"Moore AR , Zheng H , Ganesan A , et al . International multi-cohort analysis identifies novel framework for quantifying immune dysregulation in critical illness: results of the subspace consortium. Immunology [Preprint]. doi:10.1101\/2024.11.12.623298","DOI":"10.1101\/2024.11.12.623298"},{"key":"2026042806000671000_81.4.396.89","doi-asserted-by":"publisher","DOI":"10.1186\/s40635-021-00383-x"},{"key":"2026042806000671000_81.4.396.90","doi-asserted-by":"publisher","DOI":"10.1007\/s00134-021-06537-5"},{"key":"2026042806000671000_81.4.396.91","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200903-0363OC"}],"container-title":["Thorax"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/thorax-2024-222012","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T13:00:46Z","timestamp":1777381246000},"score":1,"resource":{"primary":{"URL":"https:\/\/thorax.bmj.com\/lookup\/doi\/10.1136\/thorax-2024-222012"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,2]]},"references-count":91,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,3,13]]},"published-print":{"date-parts":[[2026,4]]}},"alternative-id":["10.1136\/thorax-2024-222012"],"URL":"https:\/\/doi.org\/10.1136\/thorax-2024-222012","relation":{},"ISSN":["0040-6376","1468-3296"],"issn-type":[{"value":"0040-6376","type":"print"},{"value":"1468-3296","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,2]]}}}